Clinical Trial Update: Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab with radiotherapy as adjuvant treatment for intermediate-risk squamous cell carcinoma of the head and neck; results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Laryngeal Cancer
• Lip Cancer
• Oral Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Larynx, Lip | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-20